Centers for Disease Control and Prevention.National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005.
2.
Mason BJ, Matsuyama JR, Jue SGAssessment of sulfonylurea adherence and metabolic control. Diabetes Educ. 1995;21:52-57.
3.
Matsuyama JR , Mason BJ, Jue SGPharmacists' interventions using electronic medication event monitoring device's adherence data versus pill counts. Ann Pharmacother.1993;27:851-855.
4.
Paes AH, Bakker A., Soe-Agne CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20(10):1512-1517.
5.
Rosen MI, Beauvais JE, Rigsby MO, Salahi JT, Ryan CE, Cramer JANeuropsychological correlates of sub-optimal adherence to metformin . J Behav Med.2003;26:349-360.
6.
Rosen MI, Rigsby MO, Salahi JT, Ryan CE, Cramer JA, Inzucchi S.Electronic monitoring and counseling to improve medication adherence . Behav Res Ther.2004;42:409-422.
7.
Ciechanowski PS, Katon WJ, Russo JEDepression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med.2000;160:3278-3285.
8.
Melikian C., White J., Vanderplas A., et al. Adherence to oral antidiabetic therapy in managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther.2002;24:460-467.
9.
Sclar DA, Robison LM, Skaer TL, Dickson WM, Kozma CM, Reeder CESulfonylurea pharmacotherapy regimen compliance in a Medicaid population: influence of age, gender, and race. Diabetes Educ. 1999;25(4):531-538.
10.
Donnan PT, MacDonald TM, Morris AD; for the DARTS/MEMO Collaboration.Adherence to prescribed oral hypoglycemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med.2002;19:279-282.
11.
Meece J.Dispelling myths and removing barriers about insulin in type 2 diabetes . Diabetes Educ. 2006;32(1):9S-18S.
12.
Siminerio L.Challenges and strategies for moving patients to injectable medications. Diabetes Educ. 2006;32(suppl 2):82S-90S.
13.
Polonsky WH , Fisher L., Guzman S., Villa-Caballero L., Edelman SVPsychological insulin resistance in patients with type 2 diabetes: the scope of the problem . Diabetes Care. 2005;28(1):2543-2546.
14.
Morris AD, Boyle Dir, McMahon AD, Greene SA, MacDonald TM, Newton RW; for the DARTS/MEMO Collaboration.Adherence to insulin treatment, glycemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet. 1997;350: 1505-1510.
15.
Gerber RA, Cappelleri JC, Kourides IA, Gelfand RATreatment satisfaction with inhaled insulin in patient with type 1 diabetes: a randomized controlled trial. Diabetes Care. 2001;24:1556-1559.
16.
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29(8):1963-1972.
17.
Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med.1993;329:977-986.
18.
Turner RC, Cull CA, Frighi V., Holman RRGlycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA.1999;281:2005-2012.
19.
UK Prospective Diabetes Study Group.Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
20.
UK Prospective Diabetes Study Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet . 1998;352: 854-865.
21.
Stratton IM , Adler AI, Neil Haw, et al. Association of glycaemia with macrovascular and microvascular complications in type 2 diabetes (UKPDS 35): prospective observational study. BMJ . 2000;321:405-412.
22.
American Association of Clinical Endocrinologists.State of Diabetes in America. http://www.aace.com/public/awareness/stateofdiabetes/DiabetesAmericaReport.pdf Accessed May 20, 2006.
23.
Koro CE, Bolin SJ, Bourgeouis N., Fedder DOGlycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27(1):17-20.
24.
Saaddine JB , Cadwell B., Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002 . Ann Intern Med.2006;144(7):465-474.
25.
Ary DV, Toobert D., Wilson W., Glasgow REPatient perspective on factors contributing to noncompliance to diabetes regimen . Diabetes Care. 1986;9(2):168-172.
26.
Introduction. Diabetes Care. 2007;30:S1-S2.
27.
Boccuzzi SJ , Wogen J., Fox J., et al. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care. 2001;24(8):1411-1415.
28.
Vanderpoel DR, Hussein MA, Watson-Heidari T., et al. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis . Clin Ther.2004;26:2066-2075.
29.
Hertz RP, Unger AN, Lustik MBAdherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer sponsored health insurance. Clin Ther.2005;27(7): 1064-1073.
30.
Schectman JM , Nadkarni MM, Voss JDThe association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002;25:1015-1021.
31.
Catalan VS, Couture JA, LeLorier J.Predictors of persistence if use of the novel antidiabetic agent acarbose . Arch Intern Med.2001;161:1106-1112.
32.
Evans JM, Donnan PT, Morris ADAdherence to oral hypoglycemic agents prior to insulin therapy in type 2 diabetes . Diabet Med.2002;19:685-688.
33.
Venturini F. , Nichol MB, Sung JC, et al. Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother.1999;33:281-288.
34.
Spoelstra JA , Stolk RP, Heerdink ER, et al. Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy. Pharmacoepidemiol Drug Saf.2003;12:121-127.
35.
Dezii CM, Kawabata H., Tran M.Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J.2002;95(1):68-71.
36.
Morningstar BA, Sketris IS, Kephart GC, Sclar DAVariation on pharmacy prescription refill adherence measures by type of oral antihyperglycemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther.2002;27:213-220.
37.
Rhee MK, Slocum W., Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ. 2005;31(2):240-250.
38.
Doro P., Benko R., Kosik E., et al. Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy. Eur J Clin Pharmacol.2005;61:893-897.
39.
Balkrishnan R., Rajagopalan R., Shenolikar RA, et al. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetes patients: a retrospective data analysis. Curr Med Res Opin. 2004;20(10): 1633-1640.
40.
Dailey G., Kim MS, Lian JFPatient compliance and persistence with antihyperglycemic drug regimens: evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin Ther.2001;23(8):1311-1320.
41.
Brown JB, Nichols GA, Glauber HS, et al. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin Ther.1999;21(6): 1045-1057.
42.
Morris AD, Boyle DI, McMahon AD, et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet. 1997;350:1505-1510.
43.
Krapek K., King K., Warren SS, et al. Medication adherence and associated hemoglobin A1C in type 2 diabetes. Ann Pharmacother.2004;38:1357-1362.
44.
Kalsekar ID , Madhaven SS, Amonkar MM, et al. Depression in patients with type 2 diabetes: impact on adherence to oral hypoglycemic agents . Ann Pharmacother.2006;40:605-611.
45.
Kardas P.The DIACOM study (effect of DosIng frequency of oral Antidiabetes agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab. 2005;7:722-728.
46.
Charpentier G., Fleury F., Dubroca I., et al. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diabetes Metab.2005:31;189-195.
47.
Grant RW, Devita ND, Singer DE, Meigs JBPolypharmacy and medication adherence in patients with type 2 diabetes . Diabetes Care. 2003;26(5):1408-1412.
48.
Lawson ML, Cohen N., Richardson C., et al. A randomized trial of regular standardized telephone contact by a diabetes nurse educator in adolescents with poor diabetes control. PediatrDiabetes. 2005;6:32-40.
49.
Mendez FJ, Belendez M.Effects of a behavioral intervention on treatment adherence and stress management in adolescents with IDDM. Diabetes Care. 1997 ;20(9):1370-1375.
50.
Ellis DA, Frey MA, Naar-King S., et al. Use of multisystemic therapy to improve regimen adherence among adolescents with type 1 diabetes in chronic poor metabolic control. Diabetes Care. 2005;28(7):1604-1610.
51.
Skaer TL, Sclar DA, Markowski DJ, Won KHEffect of value-added utilities on prescription refill compliance and Medicaid health care expenditures—a study of patients with non-insulin-dependent diabetes mellitus. J Clin Pharm Ther.1993 ;18:295-299.
52.
Grant RW, Devita NG, Singer DE, Meigs JBImproving adherence and reducing medication discrepancies in patients with diabetes. Ann Pharmacother.2003;37:962-969.
53.
Littenberg B., MacLean CD, Hurowitz L. The use of adherence aids by adults with diabetes: a cross-sectional survey. BMCFam Pract.2006;7:1-5.
54.
Rubin RRAdherence to pharmacologic therapy in patients with type 2 diabetes mellitus . Am J Med.2005;118(5A):27S-34S.
55.
Kilbourne AM , Reynold CF, Good CB, Sereika SM, Justice AC, Fine MJHow does depression influence diabetes medication adherence in older patients?Am J Geriatr Psychiatry. 2005;13(3): 202-210.
56.
Lin EHB , Oliver M., Katon W., et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care. 2004;27:2154-2160.
57.
Ziemer DC, Doyle JP, Barnes CS, et al. An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting. Arch Intern Med.2006;166:507-513.
58.
Grant R., Adams AL, Trinacty CM, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care. 2007;30(4):807-812.
59.
Pladevall M. , Divine G., Williams LK, Xi H., Potts LA, Lafata JEClinical outcomes and adherence to medications measured by claims data in patients with diabetes . Diabetes Care. 2004;27:2800-2805.
60.
Hepke KL, Martus MT, Share DACosts and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care.2004 ;10(pt 2):144-151.
61.
Maier C., Mustapic D., Schustert E., Luger A., Eher R.Effect of a pocket-size tablet-dispensing device on glycaemic control in type 2 diabetic patients. Diabet Med.2006;23:40-45.
62.
Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalizations and mortality among patients with diabetes mellitus. Arch Intern Med.2006:166:1836-1841.
63.
Chao J., Nau DP, Aikens JE, Taylor SDThe mediating role of health beliefs in the relationship between depressive symptoms and medication adherence in persons with diabetes. Res Social Adm Pharm.2005;1(4):508-525.
64.
Farmer A., Kinmonth AL, Sutton S.Measuring beliefs about taking hypoglycemic medication among people with type 2 diabetes. Diabet Med.2006;23:265-270.
65.
Walker EA, Moltich M., Kramer MK, et al; for the Diabetes Prevention Program Research Group.Adherence to preventive medications: predictors and outcomes in the diabetes prevention program. Diabetes Care . 2006;29(9):1997-2002.
